Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05806762 · ClinicalTrials.gov registry record
Prediction of Rehospitalization Following a Sepsis Admission Using a Wearable Biopatch
A clinical trial of Sepsis, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT05806762 is a study of Sepsis that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 200 participants, below the 6,562-participant average among 90 other Sepsis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05806762, a study of Sepsis, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to learn about the utility of biopatches predicting 30-day readmissions in patients discharged from the hospital with sepsis. The main question\[s\] it aims to answer are: • Does the application of a biopatch provide data that can improve prediction of an unplanned 30-day readmission following a hospitalization for sepsis. Participants will be asked to wear a biopatch on their chest for 30-days following hospital discharge or until readmission to the hospital.
Conditions Studied
Interventions
- DEVICE BioIntellisense
Study Locations (1)
California
- UC San Diego Health - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2027-05-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05806762
The ClinicalTrials.gov registry entry for NCT05806762 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,562-participant average among 90 other Sepsis trials with a reported enrollment target (97% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which BioIntellisense is the first listed.
NCT05806762 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05806762 about?
NCT05806762 is a clinical study titled "Prediction of Rehospitalization Following a Sepsis Admission Using a Wearable Biopatch". The goal of this observational study is to learn about the utility of biopatches predicting 30-day readmissions in patients discharged from the hospital with sepsis. The main question\[s\] it aims to answer are: • Does the application of a biopatch provide data that can improve prediction of an un...
What is the current status of trial NCT05806762?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2023-05-01. Estimated completion is 2027-05-02.
What conditions does trial NCT05806762 study?
This clinical trial studies the following conditions: Sepsis.
What interventions are being tested in trial NCT05806762?
The interventions under investigation include: BioIntellisense (DEVICE).
Who is sponsoring clinical trial NCT05806762?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05806762 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.